| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.3348 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.3549 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.3780 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4038 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4155 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4335 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4534 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4801 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4824 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.4912 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5038 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5245 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5248 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5255 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5366 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5451 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5629 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.5909 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6035 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6053 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6089 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6117 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6174 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6408 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6417 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6492 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6567 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6626 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6677 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6686 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6817 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6837 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.6925 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7042 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7139 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7293 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7342 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7374 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7463 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7618 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.7827 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.8061 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.8211 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.8710 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.8946 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9123 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9159 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9201 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9434 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9462 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9501 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9690 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0.9965 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0035 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0104 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0265 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0342 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0362 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0521 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0681 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0932 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.0971 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1054 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1057 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1088 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1295 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1379 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1425 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1609 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1683 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1705 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1758 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.1996 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.2064 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.2086 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.2270 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.2418 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.2961 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.3090 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.3272 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.3382 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.3633 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.4009 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.4393 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.4404 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.4759 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.5404 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.5469 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.5542 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.5869 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.5991 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.6004 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.6252 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.6452 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.6613 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.6939 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.7532 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.7883 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.7897 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.8334 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.8579 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.9385 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 1.9615 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 2.0368 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 2.4675 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dilinoleoyl-GPC (18:2/18:2) | 3.2985 | Peak area | Normal |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|